ArticleJournal of inflammation research2025
Prognostic Impact of Metabolic and Inflammatory Risk for Periprocedural MI and Long-Term Events in Three-Vessel Disease Patients.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Risk stratification and management of three-vessel coronary artery disease (3VD) remains challenging. Patients with 3VD tolerate greater metabolic and inflammatory burdens than patients with single- and double-vessel coronary artery disease. This study aimed to evaluate the prognostic value of triglyceride-glucose (TyG) index and high-sensitive C-reactive protein (hsCRP), which representing metabolic and inflammatory burdens respectively in a 3VD cohort. Patients and Methods: This is a retrospective observational study, totally 4495 patients with 3VD were enrolled in the study and divided into 4 groups according to TyG (≥ or <8.5) and hsCRP (≤ or >2mg/L). The primary endpoints were periprocedural myocardial infarction (PMI) following percutaneous coronary intervention (PCI) and major adverse cardiovascular events (MACCEs). Restricted cubic spline (RCS), multivariate Cox proportional hazard models, C-index and net reclassification improvement (NRI) were used for analyses. Results: The median follow-up time was 2.4 years. 3VD patients with TyG≥8.5 and hsCRP>2mg/L exhibited 70%-145% increase risk of PMI according to different definitions. Multivariate Cox regression analyses showed that hsCRP>2mg/L was associated with approximately 30% increased risk of MACCEs in 3VD patients with TyG≥8.5 (HR: 1.31, 95% CI: 1.02-1.69, Conclusion: 3VD patients with TyG≥8.5 and hsCRP>2mg/L has significantly increased risks of PMI. HsCRP>2mg/L, alone or in combination of TyG≥8.5, has significantly increased risk of MACCEs among 3VD individuals, highlighting the necessity of managing metabolic and inflammatory burdens simultaneously in 3VD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.